Interpace Biosciences
Interpace Biosciences Q1 Revenues Up 8 Percent
The company attributed the revenue increase to improved performance in its clinical services business and increased reimbursement rates for its cancer tests.
Interpace Biosciences to Review Strategic Alternatives
The company, which was recently delisted from the Nasdaq, began a reorganization earlier this year in order to cut $7.2 million in annual costs.
Interpace Biosciences Q4 Revenues More Than Double
The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.
In Brief This Week: Thermo Fisher, BioReference Laboratories, Hologic, Invitae, Danaher, and More
News items for the in vitro diagnostics industry for the week of Feb. 22, 2021.
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
Jan 20, 2021
Interpace Bio Q3 Revenues Rise 6 Percent
Oct 20, 2020
Interpace Biosciences Q2 Revenues Decline 14 Percent
Jun 26, 2020
Interpace Biosciences Q1 Revenues Rise 53 Percent
Dec 20, 2019
Aug 13, 2019